Merck KGaA Stock Under Scrutiny as Earnings and Bio-Techne Deal Come Into Focus

Merck KGaA (XTRA:MRK) has delivered a solid return of 28.7% over the past year, but investors are now wondering if the current share price is justified by its earnings. The stock closed at around €133.95 in September, which raises questions about whether earnings can support sentiment from here.

The agreed acquisition of Bio-Techne, expected to close between late 2026 and early 2027, may reshape Merck KGaA's life science earnings profile, including future margins and cash flow mix once the combined operation is in place. The current price-to-earnings (P/E) ratio of around 24.6x is lower than the Pharmaceuticals industry average of about 22.3x.

Analysts think Merck KGaA's shares could be worth more, with one community narrative suggesting that the company is undervalued by 13%. This narrative points to digitalization efforts as a key driver of growth and productivity for the company.